Skip to main content

Orion Genomics, Novartis Collaborate On Epigenetic Biomarker Research

NEW YORK (GenomeWeb News) – Orion Genomics, a St. Louis-based epigenetic research tools and molecular diagnostics company, and Novartis Pharma's molecular diagnostics unit have entered into a multi-year collaboration and license agreement, Orion announced today.

The collaboration, aimed at discovering epigenetic markers related to a range of diseases, will involve mapping DNA methylation across the genome using Orion's MethylScope Technology.

Under the agreement, both Orion and Novartis will retain rights to independently develop and commercialize diagnostic products in their respective fields. Orion also has granted Novartis non-exclusive, world-wide rights to its PCR-based MethylScreen clinical assay technology, which is used to detect epigenetic markers in patient samples.

"[O]ur collaboration with Novartis Molecular Diagnostics aims to support the development of innovative tests which we hope will provide physicians and patients with better information to guide treatment decisions," Orion Genomics President and CEO Nathan Lakey said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.